<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02018757</url>
  </required_header>
  <id_info>
    <org_study_id>2012AA022701</org_study_id>
    <nct_id>NCT02018757</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC</brief_title>
  <acronym>SEATH</acronym>
  <official_title>Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Hospital of China Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine whether transarterial chemoembolization containing
      arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular
      carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to progression</measure>
    <time_frame>From date of randomization until the date of first documented progression, up to 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>every 3 months from randomization until the date of first documented progression, up to 24 months</time_frame>
    <description>patients proportion of CR and PR according to mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>From date of randomization until the date of first documented progression, up to 24 months</time_frame>
    <description>survival from randomization to the date of first documented progression according to the mRECIST criterion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause, up to 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Adverse Events</measure>
    <time_frame>every 3 months from randomization until the date of first documented progression, up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <arm_group>
    <arm_group_label>As2O3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be treated with TACE containing As2O3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be treated with TACE containing placebo which mimics the arsenic trioxide</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TACE containing As2O3</intervention_name>
    <description>transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol</description>
    <arm_group_label>As2O3</arm_group_label>
    <other_name>transarterial chemoembolization,TACE,As2O3,arsenious acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TACE containing placebo</intervention_name>
    <description>transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  accordance with primary hepatocellular carcinoma diagnosis standard：cytohistology
             standard or non-invasive standard.1）+2）a or 1）+2）b+3）of the following are the
             non-invasive diagnosis criteria:(1)patients with HBV or HCV related liver
             cirrhosis.(2)radiological lesion(s) in liver with arterial hypervascularity and venous
             or delayed phase washout: a.one kind of imaging technology diagnosis for those with
             lesions&gt;2cm;b.two kinds of imaging technology obtains the consistent conclusion for
             lesions with diameter of 1-2 cm.(3)serum AFP level ≥400 ug/L lasting for more than 1
             month or ≥200 ug/L lasting for more than 2 months, other diseases that may cause the
             AFP level increase can be excluded,such as pregnancy, genital or embryonic tumors and
             active hepatitis.

          -  age of 18 to 75 year,male or female

          -  life expectancy of 12 weeks

          -  Barcelona Clinic Liver Cancer (BCLC)stage B

          -  laboratory tests:(1)leukocyte&gt;3*19^9/L;(2)hemoglobin≥8.5g/dl;(3)platelet count
             ≥50*10^9/L,(4)ALT and AST were less than three times the normal limit;(5)albumin ≥ 3.0
             g/dl;(6)total bilirubin acuities 3 mg/dl;(7)prothrombin time international
             standardization ratio (PT - INR) &lt; = 2.3 or prothrombin time (PT)more than normal
             compared 3 seconds;(8)serum creatinine is less than 1.5 times the normal of the upper
             limit

          -  patients with signed informed consent

        Exclusion Criteria:

          -  concomitant malignancies distinct from HCC currently or previously

          -  allergic to subject agent(such as arsenic) or other agent related to the trial

          -  BCLC stage 0,A,C or D

          -  HCC accounting for the 70% of the liver size or more

          -  liver function Child-Pugh score of C

          -  ECOG score of 1 or higher

          -  severe heart diseases,such as congestive heart failure with cardiac function of New
             York Heart Association(NYHA)functional class II or severe, active coronary
             disease(except for who with myocardial infarction for more than 6 months) and cardiac
             arrhythmia needing medical management(except for that controllable by
             β-blockers、calcium channel blockers and digoxin )

          -  uncontrollable hypertension(diastolic blood pressure cannot be controlled below 90
             mmHg even after antihypertension treatment by antihypertensive drugs).

          -  active severe infection(grade 2 or higher according to NCI-CTCAE version 4.0)

          -  active tuberculosis or pulmonary tuberculosis cannot be excluded

          -  CNS malignancies, including intracranial metastases

          -  gastrointestinal bleeding with clinical findings in the previous 30 days

          -  chronic renal failure

          -  pregnancy or breastfeeding

          -  any other unstable conditions or circumstances possibly to jeopardise the safety or
             compliance of the subjects.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haibo Shao, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>First Hospital of China Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haibo Shao, MD,PHD</last_name>
    <phone>862483282730</phone>
    <email>haiboshao@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Peihong Wu, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gaojun Teng, MD,PhD</last_name>
    </contact>
    <investigator>
      <last_name>Gaojun Teng, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Haibo Shao, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xijing Hospital，Fourth Military Medical University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Guohong Han, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jianhua Wang, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.nhfpc.gov.cn/</url>
    <description>National Health and Family Planning Commission of the People's Republic of China</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2013</study_first_submitted>
  <study_first_submitted_qc>December 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2013</study_first_posted>
  <last_update_submitted>May 25, 2014</last_update_submitted>
  <last_update_submitted_qc>May 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>First Hospital of China Medical University</investigator_affiliation>
    <investigator_full_name>Haibo Shao</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Carcinoma, Hepatocellular</keyword>
  <keyword>primary liver cancer</keyword>
  <keyword>primary hepatocellular carcinoma</keyword>
  <keyword>transarterial chemoembolization</keyword>
  <keyword>Chemoembolization, Therapeutic</keyword>
  <keyword>arsenic trioxide</keyword>
  <keyword>arsenous anhydride</keyword>
  <keyword>diarsenic trioxide</keyword>
  <keyword>randomized controlled trial</keyword>
  <keyword>multicenter study</keyword>
  <keyword>HCC</keyword>
  <keyword>TACE</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorotrianisene</mesh_term>
    <mesh_term>Arsenic trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

